Your browser doesn't support javascript.
loading
Assessment of Interleukin 17 in Egyptian Systemic Lupus Erythematosus Patients as a Biomarker in Disease Activity.
Behiry, Mervat; Wadie, Mary; Mohamed, Nagwa Abdelghaffar; Farid, Rania; Ramadan, Hala.
Affiliation
  • Behiry M; Department of Internal Medicine, Faculty of Medicine, Cairo University, Kasr Alainy, Egypt.
  • Wadie M; Department of Internal Medicine, Faculty of Medicine, Cairo University, Kasr Alainy, Egypt.
  • Mohamed NA; Department of Clinical and Chemical Pathology, National Research Centre, Egypt.
  • Farid R; Department of Internal Medicine, Faculty of Medicine, Cairo University, Kasr Alainy, Egypt.
  • Ramadan H; Department of Internal Medicine, Faculty of Medicine, Cairo University, Kasr Alainy, Egypt.
Curr Rheumatol Rev ; 20(5): 534-543, 2024.
Article in En | MEDLINE | ID: mdl-38299415
ABSTRACT

INTRODUCTION:

Systemic lupus erythematosus (SLE) is a chronic idiopathic systemic autoimmune disorder with dysregulation of adaptive and innate immune systems. Interleukin (IL)-17 is the prototypical pro-inflammatory cytokine of T helper 17 (Th17) cells. Therefore, it contributes to the pathogenesis of human SLE.

AIM:

The aim of the research paper was the evaluation of IL-17 level as a biomarker in the SLE cohort and its relation to disease activity and analysis of IL-17 concentration in patients with lupus nephritis and non-lupus nephritis.

METHODS:

The research enrolled 45 SLE patients according to Systemic Lupus International Collaborating Clinics Classification Criteria (SLICC), and age and sex-matched. The patients underwent full history, clinical examination, laboratory investigation, and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) calculation.

RESULTS:

The mean age ± SD of the participants equaled 32 ± 11 years, and serum IL-17 in SLE cases was statistically significantly high (p < 0.001). No statistically significant correlations were reported between disease activity according to SLEDAI and IL-17. In addition, a statistically significant positive correlation was reported between IL-17 and ESR, and a high statistically significant negative correlation was reported between IL-17 and C3 and C4 (P < 0.001). A statistically significant positive correlation was reported between IL-17 and 24-hour urinary proteins with a Pvalue of 0.01.

CONCLUSION:

SLE cases demonstrated higher levels of serum IL-17, contributing to SLE pathogenesis. However, no statistically significant difference was reported between IL-17 and Lupus nephritis. IL-17 and SLE activity (SLEDAI) did not correlate. A statistically significant positive relation was reported between IL-17 and 24-hour urinary proteins. Additionally, a high statistically significant negative correlation was reported between IL-17 and C3 and C4.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biomarkers / Interleukin-17 / Lupus Erythematosus, Systemic Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: Africa Language: En Journal: Curr Rheumatol Rev Year: 2024 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biomarkers / Interleukin-17 / Lupus Erythematosus, Systemic Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: Africa Language: En Journal: Curr Rheumatol Rev Year: 2024 Document type: Article Affiliation country: